Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
swine mycoplasma hyopneumoniae live vaccine
- Development stage
- Unknown
- Lead developer
- Jiangsu Academy of Agricultural Sciences
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intranasal
01
Overview
Swine Mycoplasma live vaccine refers to a category of live attenuated vaccines designed to protect pigs against Enzootic Pneumonia, a chronic respiratory disease caused by *Mycoplasma hyopneumoniae*. These vaccines, most notably those utilizing the attenuated Strain 168 or RM48, are administered to piglets to induce both local mucosal immunity in the respiratory tract and systemic immune responses. Unlike traditional inactivated bacterins, live vaccines aim to colonize the upper respiratory tract, providing a more comprehensive immune barrier that reduces lung lesions and improves average daily gain in infected herds. While inactivated vaccines dominate the global market, live attenuated formulations are extensively utilized in the Chinese swine industry, often administered via intramuscular or intranasal routes.
- Other names
- Mycoplasma hyopneumoniae vaccine, liveM. hyo live vaccineswine mycoplasmal pneumonia live vaccineStrain 168 live vaccineStrain168 live vaccineStrain-168 live vaccine
02
Targets
Toll-like receptor 2 (TLR2)–Nuclear factor kappa B (NF-κB) signaling pathway
Beyond the preview
Go deeper on swine mycoplasma hyopneumoniae live vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on swine mycoplasma hyopneumoniae live vaccine.